Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1915801rdf:typepubmed:Citationlld:pubmed
pubmed-article:1915801lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C1136085lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C1145667lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C0443737lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C1515021lld:lifeskim
pubmed-article:1915801lifeskim:mentionsumls-concept:C1516240lld:lifeskim
pubmed-article:1915801pubmed:issue3lld:pubmed
pubmed-article:1915801pubmed:dateCreated1991-11-1lld:pubmed
pubmed-article:1915801pubmed:abstractTextThe presence of T cells binding F(ab')2 fragments of the idiotypic immunoglobulin was examined by immunofluorescence in peripheral blood of patients with monoclonal gammopathy. In 3 out of 11 tested patients, 1-15% idiotype-binding T cells of either CD4 or CD8 phenotype were found. In 1 patient both a CD4+ and a CD8+ idiotype-binding T-cell fraction were present. In 1 patient the idiotype-binding T cells also reacted with a mAb directed against the variable parts of the TCR alpha or beta chains, further indicating a clonal origin at the alpha/beta level. 3 patients had an expanded predominant T-cell receptor V gene usage based on the reactivity with the limited panel of TCR mAb, but these "clonal" T cells did not bind the idiotype. The study supports the existence of idiotype-specific T cells in peripheral blood of patients with monoclonal gammopathy. Such cells might have a regulatory role on the monoclonal B-cell clone and may be an important target for immunotherapy.lld:pubmed
pubmed-article:1915801pubmed:languageenglld:pubmed
pubmed-article:1915801pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1915801pubmed:citationSubsetIMlld:pubmed
pubmed-article:1915801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1915801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1915801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1915801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1915801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1915801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1915801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1915801pubmed:statusMEDLINElld:pubmed
pubmed-article:1915801pubmed:monthSeplld:pubmed
pubmed-article:1915801pubmed:issn0902-4441lld:pubmed
pubmed-article:1915801pubmed:authorpubmed-author:HolmGGlld:pubmed
pubmed-article:1915801pubmed:authorpubmed-author:WigzellHHlld:pubmed
pubmed-article:1915801pubmed:authorpubmed-author:MellstedtHHlld:pubmed
pubmed-article:1915801pubmed:authorpubmed-author:LefvertA KAKlld:pubmed
pubmed-article:1915801pubmed:authorpubmed-author:JansonC HCHlld:pubmed
pubmed-article:1915801pubmed:authorpubmed-author:OsterborgAAlld:pubmed
pubmed-article:1915801pubmed:authorpubmed-author:BergenbrantSSlld:pubmed
pubmed-article:1915801pubmed:issnTypePrintlld:pubmed
pubmed-article:1915801pubmed:volume47lld:pubmed
pubmed-article:1915801pubmed:ownerNLMlld:pubmed
pubmed-article:1915801pubmed:authorsCompleteYlld:pubmed
pubmed-article:1915801pubmed:pagination185-91lld:pubmed
pubmed-article:1915801pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:meshHeadingpubmed-meshheading:1915801-...lld:pubmed
pubmed-article:1915801pubmed:year1991lld:pubmed
pubmed-article:1915801pubmed:articleTitlePeripheral blood T lymphocytes in patients with monoclonal gammopathies: expanded subsets as depicted by capacity to bind to autologous monoclonal immunoglobulins or reactivity with anti-V gene-restricted antibodies.lld:pubmed
pubmed-article:1915801pubmed:affiliationDepartment of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden.lld:pubmed
pubmed-article:1915801pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1915801pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1915801lld:pubmed